Background: Hib-related meningitis and pneumonia are severe and debilitating infectious disorders that can affect anyone. The protection provided by the Haemophilus influenzae immunisation was long-lasting.
 Purpose of the research: The creation of a lipid nanoparticle (LNP) RNA vaccine against the genes hcsA and hcsB that allow the movement of capsular polysaccharides over the outer membrane in Haemophilus influenzae type b. Research type: Screening experimental study. Methodology: In this study, we created an LNP-RNA vaccine for Haemophilus influenzae type b hcsA and hcsB, which are involved in the pathogen's ability to transfer capsular polysaccharides through its outer membrane. Lipid nanoparticles with a particle diameter of roughly 87 nanometers made up the vaccine delivery system. Results: In preclinical experiments conducted on animals, the vaccine's efficacy was 91%, while in Phase 1/2 clinical trials, it was only about 85%. Compared to other conventional vaccines, it had superior biological activity and fewer adverse effects. Conclusion: In our investigation, the vaccination proved a promising and effective preventative measure against bacterial illness brought on by HA.